Ran Wei
Weifang Medical University(CN)Changzhou University(CN)Shandong First Medical University(CN)
Publications by Year
Research Areas
Advanced Breast Cancer Therapies, Breast Cancer Treatment Studies, HER2/EGFR in Cancer Research, Gastric Cancer Management and Outcomes, Cancer-related Molecular Pathways
Most-Cited Works
- → Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial(2022)524 cited
- → Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study(2021)369 cited
- → Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes(2024)178 cited
- → Osteopontin -- a promising biomarker for cancer therapy(2017)159 cited
- → Prenatal Immune Challenge Is an Environmental Risk Factor for Brain and Behavior Change Relevant to Schizophrenia: Evidence from MRI in a Mouse Model(2009)154 cited
- → Two peptides, TsAP-1 and TsAP-2, from the venom of the Brazilian yellow scorpion, Tityus serrulatus: Evaluation of their antimicrobial and anticancer activities